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Background: Hepatocellular carcinoma (HCC) still represents an unmet medical need. Epigenetic inactivation of
tumor suppressor genes like RASSF1A or APC by overexpression of DNA methyltransferases (DNMTs) has been
shown to be common in HCC and to be linked to the overall prognosis of patients. Inhibitors of protein and
histone deacetylases (DACi) have been demonstrated to possess strong anti-tumor effects in HCC models.
Methods: We therefore investigated whether DACi also has any influence on the expression and activity of DNMTs
and methylated target genes in HepG2 and Hep3B cell culture systems and in a xenograft model by
immunohistochemistry, westernblotting, RT-qPCR and methylation-specific PCR.
Results: Our findings demonstrate a rapid inhibition of DNMT activity 6 h after treatment with 0.1 μM of the
pan-DACi panobinostat. A downregulation of DNMT mRNAs and protein were also observed at later points in time.
This loss of DNMT activity and expression was paralleled by a diminished methylation of the target genes RASSF1A
and APC and a concomitant re-expression of APC mRNA and protein. Analysis of HepG2 xenograft specimens
confirmed these results in vivo.
Conclusion: We suggest a dual mode of action of DACi on DNA methylation status: a rapid inhibition of
enzyme activity due to interference with posttranslational acetylation and a delayed effect on transcriptional
control of DNMT genes by HDAC or miRNA mechanisms.
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Hepatocellular carcinoma (HCC) is the most common
primary tumor of the liver and represents an unmet
medical need, being among the most common tumor
diseases and causes of cancer related deaths worldwide
and showing a rising incidence also in Western countries
[1-3]. Although the multi-kinase inhibitor sorafenib has
recently been approved for treatment of advanced stage
HCC, the overall efficacy still remains dissatisfying [4].* Correspondence: steffen.zopf@uk-erlangen.de
1Department of Medicine 1, University Hospital Erlangen, Ulmenweg 18,
Erlangen 91054, Germany
Full list of author information is available at the end of the article
© 2012 Zopf et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orBesides genetic alterations, changes in chromatin have
recently been identified to contribute to tumorigenesis
[5]. These reversible modifications are considered to
contribute to tumor suppressor gene inactivation by
means of DNA methylation, histone modifications or
miRNA expression. Expression of DNA methyltrans-
ferases (DNMT) has been shown to be associated with
liver cancer formation and DNA hypermethylation [6,7],
especially in the presence of hepatitis B or hepatitis C
viruses [8-10] and has been linked to poor prognosis
[11]. Today, three DNMTs have been identified in
human cells. While DNMT1 methylates newly synthe-
sized DNA during cell division (maintenance DNMT),
DNMT3a and DNMT3b act on methylation of CpGd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cesses (de novo DNMT) [12]. Genes that are commonly
affected by DNA methylation include both the tumor
suppressors RASSF1A (Ras association domain family 1
isoform A) and also APC (adenomatous polyposis coli).
Both genes have been shown to be commonly inacti-
vated in human hepatocellular carcinoma and to influ-
ence the overall prognosis of patients and therefore
represent interesting targets for reversing DNA methyla-
tion status [13-17].
Besides DNA methylation, post-translational modifica-
tions such as acetylation, SUMOylation or phosphoryl-
ation occurring at amino acid residues in histone
proteins have also been identified as strong epigenetic
regulators of gene transcription. Previously, we have
shown that expression of histone deacetylases (HDAC)
is significantly associated with HCC grading and that
HDAC2 represents an independent prognostic factor in
HCC [18]. While inhibition of HDAC is usually attribu-
ted to transcriptional control of cell cycle regulators
like p21cip1/waf1 [19], additional effects involving non-
nuclear protein modifications have recently been
described, e.g. the interaction with chaperones such as
heat shock protein 90 (HSP90) [20,21]. Although these
cellular targets of deacetylases are not well known today,
some reports confirm a transcriptional control of
DNMT by HDAC [22,23].
Panobinostat is a novel orally available pan-deacetylase
inhibitor with broad anti-tumor activity [24]. Our own
previous results showed a significant inhibition of HCC
growth in vitro and in xenograft models in vivo which
were mediated by alternative pathways of apoptosis
induction such as activation of the unfolded protein
response [25]. We therefore investigated whether pano-
binostat also influences the activity of DNMT in HCC
cell lines and if this affects the expression and methyla-
tion status of CpG promoter islands of known tumor
suppressor genes in HCC models. We can show here
that panobinostat exerts a dual effect on DNMT activity
and expression, indicating that deacetylase inhibitors can
also indirectly control DNA methylation status.
Methods
Cell culture
The human hepatocellular carcinoma cell lines HepG2
(p53wt) and Hep3B (p53−/−) were cultured on six-well
tissue culture plates (Becton Dickinson, Mannheim, Ger-
many) in RPMI-1640 (Biochrom, Berlin, Germany) or
Dulbecco’s modified Eagle’s medium (DMEM, Biochrom,
Berlin, Germany) containing 10% fetal calf serum (Bio-
chrom), penicillin (107 U/l) and streptomycin (10 mg/l)
at 37 °C in an atmosphere containing 5% CO2. All cell
lines were obtained from the German Collection of Micro-
organisms and Cell Cultures (DSMZ, Braunschweig,Germany). Cells were starved for 24 h in medium contain-
ing 0.125% FCS to achieve cell cycle synchronization and
then washed twice with phosphate-buffered saline (PBS;
Biochrom), treated with trypsin EDTA (0.05% Trypsin,
0.02% EDTA; Biochrom), seeded at a density of 0.5x106
per well [25]. Panobinostat was a gift from Novartis
Pharma AG, Basel, Switzerland, and was dissolved in
dimethylsulfoxide (DMSO; Sigma, Deisenhofen, Germany)
and then further diluted with culture medium [25]. Cells
were treated with 0.1 μM panobinostat for 6 to 72 h and
then processed for further analyses.HepG2 xenograft samples
Samples from previously established xenografts of
HepG2 cells to male athymic nu/nu NMRI mice (Harlan
Winkelmann GmbH, Borchen, Germany) were used
for this study [25]. HepG2 cell lines were harvested
and resuspended in sterile physiologic NaCl solution.
5.0 × 106 cells were injected subcutaneously into the
flank of 6 to 8 week old male mice (mean weight
38.2 +/− 4.3 g). Eight animals were used for each treat-
ment group. Animals were kept in a light and
temperature controlled environment and provided with
food and water ad libitum. Tumor size was determined
daily by measurement using a caliper square. When sub-
cutaneous tumors reached a diameter of 7 mm, daily i.p.
treatment with panobinostat (10 mg/kg) or vehicle
(physiologic saline solution) was started. Animals were
sacrificed by cervical dislocation and tumor samples col-
lected after 1, 7 and 28 days of treatment or when reach-
ing the termination criteria (e.g. weight loss > 20%,
tumor diameter > 25 mm or tumor ulceration through
the skin). Tumor and tissue samples were fixed in 10%
phosphate-buffered formalin or snap-frozen in liquid ni-
trogen. All animals received humane care. The study
protocol complied with the institute’s guidelines and was
approved by the Government of Lower Franconia
(Würzburg, Germany, file number 54–2531.31-3/06)
prior to the commencement of the experiments. Hep3B
cells proved not to be tumorigenic in NMRI mice and
were therefore not used for in vivo experiments.Measurement of DNMT activity
Nuclear protein was isolated with EpiQuik™ Nuclear Ex-
traction Kit I (Epigentek, Brooklyn, NY, USA) from cells
exposed to panobinostat or from untreated control cells.
After protein quantification with Total Protein Kit
(Micro Lowry, Peterson’s Modification; Sigma-Aldrich
Chemie GmbH, Munich, Germany), 12 μg of nuclear
protein was used to measure total DNMT activity
with the EpiQuik™ DNA Methyltransferase Activity/
Inhibition Assay (Epigentek) in accordance with the
manufacturer’s instructions.
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Total cellular RNA was extracted using the RNeasy Kit
(Qiagen, Hilden, Germany) in accordance with the man-
ufacturer’s instructions. Reverse transcription into cDNA
was performed using Superscript III RNAse H-reverse
transcriptase (Live Technologies, Darmstadt, Germany)
with dT15 (TIB-Biomol, Berlin, Germany) and random
hexamer primers (Promega, Heidelberg, Germany) as
previously described [26]. QuantiTect Primers for
DNMT1, DNMT3a, DNMT3b, APC, RASSF1A and
GAPDH were purchased from Qiagen and subjected to
quantitative real-time RT-PCR on a LightCycler system
(Roche Molecular Biochemicals, Mannheim, Germany)
using the LightCycler FastStart DNA Master SYBR
Green I Kit (Roche Molecular Biochemicals). Results
were analyzed with the LightCycler software and nor-
malized to GAPDH mRNA content for each sample.
Quantitative methylation-specific real-time PCR
Total DNA was extracted from cell culture samples and
tissue specimens from nude mice by using the DNeasy
Blood and Tissue Kit (Qiagen). DNA was then subjected
to sodium bisulfate conversion using the EpiTect Bisul-
fite Kit (Qiagen). Bisulfite converted DNA was then
used to perform a quantitative methylation-specific PCR
(qMSP) with primers and TaqMan probes (see Table 1)
specific for nucleotide sequences containing methylated
cytosines at CpG positions [27]. qMSP was performed
using the EpiTect MethyLight PCR Kit (Qiagen) in
accordance with the manufacturer’s instructions.
Protein extraction and Westernblot analysis
Whole cell lysates were prepared from panobinostat-
treated cells, untreated controls and xenograft tissue






PCR parameter: Denaturation: 95°C, 10 min. (1 cycle),
Amplification: 95°C, 10 sec.; 64°C, 60 sec. (50 cycle);
Denaturation: 40°C, 30 sec. (1 cycle)
RASSF1A
Forw. 5´-GCG TTG AAG TCG GGG TTC-3´
Rev. 5´-CCC GTA CTT CGC TAA CTT TAA ACG-3´
TaqMan-Probe: 5´-FAM-ACAAACGCGAACCGAACGAAACCA-
TAMRA-3M
PCR parameter: Denaturation: 95°C, 10 min. (1 cycle),
Amplification: 95°C, 10 sec.; 63°C, 60 sec. (50 cycle);
Denaturation: 40°C, 30 sec. (1 cycle)extracted from cultured cells by adding 2X sample buffer
(10 mM sodium chloride, 0.5% Nonidet NP40 (Amresco,
Solon, OH, USA), 20 mM Tris–HCl pH 7.4, 5 mM mag-
nesium chloride, 10 μg/ml complete protease inhibitor
cocktail (Roche Diagnostics, Mannheim, Germany),
1 mM phenylmethylsulfonylfluoride). DNA was shared
by pipetting up and down for 3 minutes at room
temperature. Samples were boiled at 95°C for 15 minutes,
centrifuged at 13,000 rpm for 10 seconds and then sub-
jected to 14% SDS-PAGE (Life Technologies). After
blocking overnight at 4°C in a buffer containing PBS,
0.1% Tween-20 and 5% low fat milk powder, nitro-
cellulose membranes were incubated for 90 minutes
with primary antibodies. Antibodies against DNMT1,
DNMT3a, DNMT3b (Cell Signaling Technology, Denvers,
MA, USA), APC, RASSF1A (both from Abcam, Cam-
bridge, UK) and β-actin (Sigma, Deisenhofen, Germany)
were used. Membranes were washed three times for
10 minutes in a buffer containing PBS and 0.1% Tween-20
and were incubated with a peroxidase coupled secondary
antibody (1:1,000, Pierce, Rockland, IL, USA) to visualize
responsive bands after incubation with West Pico lumi-
nescence substrate (Pierce). Densitometry analysis was
performed by peak intensity analysis on a GeneGnome
image capture and analysis system (GeneGnome, Syngene,
UK). Bands were normalized to β-actin expression which
was used as an internal loading control.
Immunohistochemistry
Formalin-fixed and paraffin-embedded xenograft tumour
samples were cut into 5 μm sections deparaffinised using
graded alcohols. Antigen retrieval was performed by
heat-induced epitope retrieval in pH= 9 antigen retrieval
buffer (Dako, Glostrup, Denmark) at 95°C for 60 minutes.
Endogenous peroxidase blocking was carried out for
10 minutes with peroxidase blocking reagent (Dako).
Subsequently, the primary antibody against DNMT1
(monoclonal, mouse anti-human, Antibodies-Online,
Aachen, Germany, ABIN466002, 1:50) and DNMT3a
(polyclonal, rabbit anti-human, Santa Cruz Biotechnol-
ogy, Heidelberg, Germany, sc-20703, 1:200) was applied
for 30 minutes at RT. For detection of the primary anti-
bodies the ready-to-use REAL™ EnVision™ Detection
System (Dako) was used in accordance with the manu-
facturer’s instructions. The EnVision staining system is
based on an HRP labeled dextran polymer, which is con-
jugated to secondary antibodies eliminating the nonspe-
cific staining background resulting from endogenous
avidin-biotin activity. Visualization was performed using
diaminobenzidine (DAB) as the chromogen substrate
being a part of the REAL™ EnVision™ Detection System.
Slides were counterstained with hematoxylin. The
stained slides were digitalized using the ImageAccess 9
Enterprise software (Imagic Bildverarbeitung, Glattbrugg,
Figure 1 Panobinostat affects activity and expression of DNA
methyltransferases in vitro. (A) Total DNMT activity was evaluated
in HepG2 and Hep3B cells treated with 0.1 μM panobinostat for the
indicated points in time. Results are the mean remaining DNMT
activity ± relative error of three independent experiments and are
expressed relative to values of untreated controls with a set value of
1.0 for each point in time. * P< 0.05 vs. untreated controls. (B) and
(C) Quantitative RT-PCR analysis of expression of DNMTs in HepG2
(B) and Hep3B (C) cells after treatment with 0.1 μM panobinostat.
Results were normalized to the GAPDH level of each sample and
represent mean± relative error of three independent experiments
and are expressed relative to mRNA levels of untreated controls at
each point in time using the set value 1.0.
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DNMT3a nuclear expressing tumor cells were evaluated
for the 3 different high power fields (400 magnification)
using the particle analysis module with the optimized
binarisation method of the image analysis system.
Statistical analysis
Statistical analysis was performed using SPSS 15.0.1 for
Windows (SPSS Inc., Chicago, IL, USA). Significance
was calculated using the t-test for paired samples.
P < 0.05 was regarded as significant (*).
Results
Panobinostat inhibits DNMT activity and expression
in vitro
After only 6 h of treatment, incubation of HepG2 and
Hep3B cells led to a rapid and significant decrease in
total DNMT activity by 46.7% and 47.4%, respectively.
At later points in time, DNMT activity was stably
reduced by approximately 20% in both cell lines, except
for the 24 and 72 h time point in HepG2, where an in-
hibition of more than 40% was observed (Figure 1A).
Expression of DNMT1, DNMT3a and DNMT3b were
then investigated by quantitative real-time RT-PCR.
Panobinostat treatment significantly repressed mRNA
for DNMT1 and DNMT3a in both cell lines while no
changes were observed in DNMT3b levels (Figure 1B/C).
These findings were corroborated by westernblot analysis
showing a strong reduction of DNMT1 and DNMT3a
protein in both cell lines but not of DNMT3b (Figure 2).
Here, only a transient decrease in protein levels was
observed after 24 to 48 h in both cell lines. Although
mRNA levels in total were rapidly decreased by panobi-
nostat, protein expression was significantly reduced after
only 24 h and remained suppressed until 72 h for
DNMT1 and DNMT3a.
Effects of panobinostat on target gene methylation and
expression in vitro
We next investigated whether the inhibition of DNMT
activity and expression is also reflected on the methyla-
tion pattern of known hypermethylated tumor suppres-
sor genes. In order to do so, quantitative methylation
specific PCR was performed for APC and RASSF1A in
cells treated with 0.1 μM panobinostat for 6 to 72 h and
expressed relative to the levels of untreated controls
at the given points in time (Figure 3). Overall, Hep3B
cells seemed to be more sensitive to the DACi-mediated
inhibition of DNA methylation as shown by a significant
and strong reduction of methylated APC after only 6 h.
While methylation was suppressed by approximately
80% here, APC methylation returned to the level of
untreated controls after 24 h. RASSF1A showed a slight
reduction in methylation at 12 h but only proved to besignificant (60% reduction) at 72 h. In HepG2, APC
methylation was significantly reduced after only 24 h of
treatment while no change was observed for RASSF1A.
In line with the reduction of methylation, an increased
expression of APC was observed in both cell lines,
reaching the highest level at 48 h for Hep3B and at 72 h
Figure 2 Westernblot analysis of DNMT expression. HepG2 and Hep3B cells were incubated with 0.1 μM panobinostat for the indicated
points in time. Western blot results show representative examples for expression of DNMT1, DNMT3a and DNMT3b as well as β-actin which
served as an internal control. Densitometry values are relative to untreated controls with a set value of 1.0 for each point in time.
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methylation of RASSF1A showed no significant change
in expression induced by panobinostat (Figure 3D).
Panobinostat influences methylation and gene expression
pattern in vivo
To address whether panobinostat also influences expres-
sion of DNMTs and related target genes in vivo, we ana-
lyzed HepG2 xenograft samples from a previously
described nude mouse model [25]. Animals were treated
with daily intraperitoneal injections of 10 mg/kg panobi-
nostat. After only 1 day expression of all DNMTs wereFigure 3 Regulation of DNA methylation and expression of target ge
RASSF1A (B) was detected by quantitative methylation-specific PCR in Hep
total mRNA for APC (C) and RASSF1A (D) was analyzed using quantitative r
Results are mean± relative error of three independent experiments and are
* P< 0.05 vs. untreated controls.reduced by approximately 40% compared to untreated
controls. The observed reduction in expression was sta-
tistically significant (P<0.05) for DNMT1 and DNMT3a
(Figure 4A). Although expression of DNMT3b was also
reduced in the in vivo setting, the results were not of
statistical significance (P= 0.06, 0.28 and 0.08 at day 1, 7
and 28, respectively), and therefore confirmed the above
described in vitro findings.
The methylation status and total mRNA expression of
APC and RASSF1A were analyzed from these samples
after 7 and 28 days of treatment (Figure 4B). Interest-
ingly, while the methylation status of APC did not differnes after panobinostat treatment. DNA methylation of APC (A) and
G2 and Hep3B cells treated with 0.1 μM panobinostat. Expression of
eal-time RT-PCR and normalization to GAPDH content of each sample.
expressed relative to the untreated controls with a set value of 1.0.
Figure 4 Effect of panobinostat on DNMT and target gene
expression in vivo. HepG2 xenograft specimens were analyzed for
expression of (A) DNMTs after 1, 7 and 28 days of daily i.p.
injections of 10 mg/kg panobinostat. Results were normalized to
the GAPDH content of each sample and represent mean± relative
error of 5 to 10 independent samples per group and are
expressed relative to expression levels of untreated control
animals with the set value of 1.0 for each point in time. (B)
Methylation status and total expression level of APC and RASSF1A
were analyzed at day 7 and day 28 of panobinostat treatment.
Results are normalized to levels of untreated controls. Methylation
of RASSF1A was not detectable in untreated controls and in
treated animals at day 7. * P< 0.05 vs. untreated controls.
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APC was induced 2.5-fold. Methylated RASSF1A was
not detectable at day 7 in either the untreated controls
or the treated animals, however, a reduction of approxi-
mately 50% was measured at the end of the study period
in the treated animals as compared to the controls.
Expression of RASSF1A was not elevated at this point in
time but showed a significant increase at day 7.
These results were confirmed by immunohistochemical
analyses after 28 days of treatment with 10 mg/kg pano-
binostat (Figure 5). Nuclear expression of both DNMT1
and DNMT3a was significantly reduced in HepG2 xeno-
graft samples. While DNMT1 and DNMT3a were
expressed in 83.3% and 84.6% of all cells in untreated
controls, only 10.7% and 20.0% stained positive for these
markers at the end of the treatment period.Discussion
Gene silencing by epigenetic mechanisms like DNA
methylation or histone acetylation has been shown to
contribute to HCC development [29-31]. These epigen-
etic mechanisms alone or in combination with genetic
modifications like mutations can lead to the inactivation
of tumor suppressor genes such as RASSF1A or APC
and thus promote hepatocarcinogenesis [32-36]. While
RASSF1A has been demonstrated to be hypermethylated
in several series of clinical HCC specimens, other poten-
tial candidates such as p16 (CDKN2a), retinoic acid
receptor (RAR) or H-cadherin (CDH13) are reported to
be low or unmethylated and were therefore not consid-
ered to be suitable target genes for our study [30,37,38].
The reversal of epigenetically silenced genes has there-
fore received increasing attention recently and various
studies aimed at reversing the hypermethylated or
hypoacetylated phenotype in tumors. Promising pre-
clinical results using DNMT inhibitors like 5-azacytidine,
5-aza-2’-deoxycytidine or zebularine have been obtained
in HCC models [39-41]. Similarly, various histone dea-
cetylase inhibitors, e.g. trichostatin A, SAHA, or the novel
pan-deacetylase inhibitor panobinostat have been investi-
gated in HCC cell culture and animal models showing a
high efficacy in inhibiting tumor cell growth. Furthermore,
we recently reported a good safety profile of panobinostat
in combination with sorafenib in a patient with metastatic
HCC [25,42-44]. While the classically considered mode of
action of these compounds is regarded as interfering with
chromatin structure and regulating the accessibility of
transcriptional complexes to the DNA [19], recent evi-
dence suggests that modifying non-histone proteins con-
tributes to the potent effects of deacetylase inhibitors in
cancer cells [25,45]. In line with this view, recent data con-
firms that DNMTs can also be inhibited by deacetylase
inhibitors [23,46]. We have demonstrated here for the first
time that treatment with the pan-deacetylase inhibitor
panobinostat rapidly reduces the activity of DNMT1 and
DNMT3a in two liver cancer cell lines in vitro after only
6 h of incubation and independent of their p53 status while
the expression of these enzymes is affected only at later
points in time. These data indicate that panobinostat leads
to a rapid inactivation of the enzymatic function of
DNMTs, probably by interfering with the protein folding
and acetylation status of these proteins which is also
reflected by a rapid decrease in the methylation levels of
APC. This hypothesis is supported by a recent report on
novel acetylation sites in lysine residues of DNMT1 that
could be influenced by class III HDAC enzymes [47].
DNMT1 was also shown to be stabilized by HDAC1
mediated deacetylation and protection from proteasomal
degradation, which represents a target of panobinostat, in-
dicating a cross-dependency of acetylation and protein
function [46]. Additionally, it was also demonstrated that
Figure 5 Immunohistochemical analysis of DNMT1 and DNMT3a expression. HepG2 xenografts were treated with daily i.p. injections of
10 mg/kg panobinostat for 28 days. Untreated controls show a high nuclear expression of both DNMTs, while a significant reduction in
expression is observed in treated samples. Bar diagram shows mean percentage of positive cells ± standard deviation of n = 5 in each group.
* P< 0.05 vs. untreated controls. Bar represents 20 μm (400× magnification) for overview and 10 μm (1000 x magnification) for detailed areas
(marked by a rectangle).
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mediated degradation of DNMT1 and could thus also con-
tribute to the reduced expression observed in our model
[48]. The here observed delayed downregulation of
DNMT mRNA and protein could also be attributed to a
decreased mRNA stability as was previously demonstrated
for DNMT1 and DNMT3b after treatment withTrichosta-
tin A in Jurkat or endometrial cells [23,49]. Panobinostat
was shown to downregulate DNMT1 without affecting
DNMT3a and 3b in human breast cancer cells and human
acute leukemia cells while we observed an additional effect
on DNMT3a in the used HCC cell lines [48,50]. Here we
found a downregulation of total DNMT activity and sup-
pression of DNMT1 and DNMT3a protein expression but
not of DNMT3b. In contrast to the known concept of
maintenance and de novo DNMTs, it was shown that the
loss DNMT1 can be compensated by DNMT3b [51,52],
confirming our results of a residual DNMT activity after
panobinostat treatment. These findings demonstrate di-
vergent effects of deacetylase inhibitor treatment onindividual DNMTs dependent on the cell type and the
intracellular context. Additional regulatory effects respon-
sible for this phenomenon could involve the altered
miRNA profile after treatment with deacetylase inhibitors
[53-55]. We have previously shown that panobinostat is
a strong modulator of miRNA expression in liver cancer
cell lines [56] and it was also demonstrated by others
that various miRNAs, e.g. miR-29, miR-148 or miR-185,
can regulate the expression of DNMTs [57-61] and thus
crosslink deacetylase inhibition to mechanisms of DNA
methylation [22,23,62].
Interestingly, panobinostat affects the expression of the
maintenance DNMT1 and of DNMT3a, which is (toge-
ther with DNMT3b) considered as a de novo DNA
methyltransferase acting during DNA replication and cell
division [12]. An overexpression of DNMTs has previ-
ously been reported in HCC, in precancerous cirrhotic
lesions and in dysplasias, indicating a strong contribution
of epigenetic events in HCC development [6,7,11,33,63].
In line with our previously reported data on inhibition of
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delayed effect on target gene methylation and reexpres-
sion was observed in both cell lines for APC at 48 and
72 h, respectively. We therefore propose a dual mode of
action of pan-deacetylase inhibitors such as panobinostat
on epigenetic control of gene expression: deacetylase
inhibitors primarily influence the acetylation status and
function of various cytosolic and nuclear proteins includ-
ing DNMTs. The rapid inhibition of DNMT activity
could be attributed to alterations in the protein folding
due to impaired acetylation. This also influences the
turnover of affected proteins and could lead to the pre-
viously described activation of the unfolded protein
response and induction of non-canonical apoptosis path-
ways [25]. Deacetylase function also controls the acetyl-
ation status of histones which, together with DNMTs
and putative miRNAs, control transcriptional processes.
This not only leads to the well described upregulation of
tumor suppressor genes such as p21cip1/waf1 [19], but also
to the suppression of DNMT expression and alterations
in miRNA profiles [53,62] which additionally affect the
translational processes leading to the desired growth-
inhibitory and pro-apoptotic effects of deacetylase inhibi-
tors in tumor cells.
Conclusion
In summary, our data indicates that, in addition to the
epigenetic activity, deacetylase inhibitors act on protein
folding and function which mediates various additional
effects such as activation of the unfolded protein response
or transcriptional and translational control of tumor sup-
pressor genes. Further studies are urgently required in
order to better understand this multitude of effects (in
particular the effects on miRNA and cellular acetylome).
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